Biotech Assistant
Share useful research with your peers
in · Share on LinkedIn ↗
COMPANY RESEARCH

Beijing Kawin Technology Share-Holding Co., Ltd.

Beijing Kawin Technology Share-Holding is a China-based biopharmaceutical developer working on treatments for viral and immune-related diseases. Its corporate description identifies an innovative drug-discovery and development focus supported by internal research and pharmaceutical-development capabilities. The Shanghai Stock Exchange STAR Market company page corroborates the issuer and its stock code 688687, while the official company website describes its research platforms and corporate history. Its drug-development programs focus on antiviral and immunology-related therapeutic approaches.

Publicly Listed BiopharmaInfectious disease & vaccinesImmunology & inflammation
My private notesAsk the research assistant ↗

Company at a glance

Corporate information

Company entity
Beijing Kawin Technology Share-Holding Co., Ltd.
Founded
Not verified
Ownership / capital status
Publicly tradedPublicly listed
LinkedIn company page
Independent company page not verified

Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.

Listed issuer and R&D focus

SSE STAR: 688687

biologics · antiviral-medicines · immunology

viral-diseases · immune-diseases

Last independently verified:

Disease tags match recorded text mentions and require program-level verification.

Technology, programs & evidence

Beijing Kawin Technology Share-Holding is a China-based biopharmaceutical developer working on treatments for viral and immune-related diseases. Its corporate description identifies an innovative drug-discovery and development focus supported by internal research and pharmaceutical-development capabilities. The Shanghai Stock Exchange STAR Market company page corroborates the issuer and its stock code 688687, while the official company website describes its research platforms and corporate history. Its drug-development programs focus on antiviral and immunology-related therapeutic approaches.

Business, technology & evidence

  • SecuritiesSSE STAR: 688687

Individual program detail is not recorded. Consult the original sources below.

Related news & literature

Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.

Showing 0 / 0 related items

No cataloged update explicitly mentions this company.

Same-field reading (not company-specific)

Research this company together

Discussions are for signed-in members. Personal notes remain separate from company research.

Sign in to join

Sources & open questions

    1. Official issuer and R&D disclosure · Beijing Kawin Technology Share-Holding Co., Ltd. ↗Beijing Kawin Technology Share-Holding Co., Ltd. ·
    2. Official issuer and R&D disclosure · Beijing Kawin Technology Share-Holding Co., Ltd. ↗Beijing Kawin Technology Share-Holding Co., Ltd. ·
    3. Official issuer and R&D disclosure · Beijing Kawin Technology Share-Holding Co., Ltd. ↗Beijing Kawin Technology Share-Holding Co., Ltd. ·
    4. Official issuer and R&D disclosure · Beijing Kawin Technology Share-Holding Co., Ltd. ↗Beijing Kawin Technology Share-Holding Co., Ltd. ·

    Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.

    AI assistant ↗